The carboxy-terminal region of major histocompatibility complex class I (MHC I) molecules is required for the rapid internalization mediated by Kaposi's sarcoma-associated herpesvirus (KSHV) proteins K3 and K5. The cytoplasmic tail of MHC I contains highly conserved serine phosphorylation sites that have been implicated in intracellular trafficking. Indeed, in vivo labeling experiments reveal a lack of MHC I phosphorylation in K5-transfected HeLa cells. Phosphorylation of the MHC I tail was restored upon mutation of the PHD/LAP domain of K5. However, deletion and mutation studies of the MHC I tail show that both K3 and K5 are able to downregulate MHC I lacking the conserved phosphorylation site. This result suggests that inhibition of phosphorylation reflects, but does not cause, MHC I internalization. Interestingly, K3 and K5 differ from each other, as well as from human immunodeficiency virus nef, with respect to the minimal MHC I tail sequences required for MHC downregulation. These data support the notion that K3 and K5 downregulate MHC I molecules by a distinct molecular mechanism that is different from other viral immune evasion molecules.
INTRODUCTION

Cytotoxic T lymphocytes (CTLs) play a central role in antiviral immunity. Infected target cells are recognized by CD8
ϩ CTLs upon display of virus-derived peptides by MHC I molecules at the cell surface (Townsend and Bodmer, 1989) . MHC I-bound peptides of eight or nine amino acids in length are usually generated in the cytosol by the ubiquitin proteasome complex and are translocated into the endoplasmic reticulum (ER) by the peptide transporter TAP (Heemels and Ploegh, 1995) . Since viruses evolved under the selective pressure of the MHC system, they have developed countermeasures against antigen presentation. Each and every step of this pathway seems to be targeted by one viral species or another. Members of the herpesvirus family seem to be particularly ingenious in devising strategies to circumvent the MHC I pathway. Herpesviral MHC I inhibitory mechanisms include the inhibition of crucial steps in antigen processing such as peptide transport or the modification of cellular protein transport pathways to redirect MHC I maturation (reviewed by Früh et al., 1999) .
Another virus that sabotages MHC I antigen presentation is the human immunodeficiency virus (HIV). HIV has developed two different strategies to downregulate MHC I. Newly synthesized MHC I molecules are disposed of in the ER by the HIV protein vpu. Vpu is anchored in the ER membrane and binds to the cytoplasmic domain of MHC class I as well as the cellular protein complex ␤-TrCP (␤-transducin repeat-containing protein) that targets proteins for degradation (Margottin et al., 1998) . Vpu thus connects this protein complex to MHC I molecules that are not normally degraded by this route. In addition, HIV mediates the rapid internalization of MHC I via its small multifunctional, cytoplasmic protein nef (reviewed in Collins and Baltimore, 1999) . During this process, MHC I molecules are targeted to the transGolgi network (TGN) by an interaction of nef with the TGN protein PACS-1 (Piguet et al., 2000) and rerouting of MHC I occurs via a PI 3-kinase-dependent pathway (Swann et al., 2001) .
Recently, two open reading frames encoded by the gamma-2 herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) were also shown to mediate the rapid internalization of MHC I (Coscoy and Ganem, 2000; Ishido et al., 2000b) and that of the costimulatory molecules B7-2 and ICAM-1 (Ishido et al., 2000b) . KSHV has been consistently found in Kaposi's sarcoma (KS), the most common AIDS-related malignancy (reviewed in Sarid et al., 1999) . Similar to HIV-nef, MHC I molecules seem to be rerouted to the endosomal/lysosomal pathway. However, K3 and K5 most likely represent ER-resident molecules that span the ER membrane, whereas nef is tethered to the plasma membrane. In K3-or K5-transfected cells, MHC I molecules mature normally and travel to the cell surface where they are rapidly internalized (Coscoy and Ganem, 2000; Ishido et al., 2000b) . The molecular mechanism by which K3 and K5 regulate the rapid internalization of MHC I is not known. Interestingly, replacing the carboxy-terminal portion of CD8 with the cytoplasmic domain and the transmembrane domain of MHC I was sufficient to render CD8 molecules susceptible to K3-and K5-mediated degradation (Ishido et al., 2000a,b) . Therefore, it can be assumed that residues in the MHC I carboxy-terminal region are responsible for internalization. The MHC I cytoplasmic domain contains highly conserved residues including a serine phosphorylation site (Guild and Strominger, 1984a; Vega and Strominger, 1989) . The spontaneous internalization of MHC I seems to require the presence of a full-length cytoplasmic tail (Capps et al., 1989; Davis et al., 1997; Vega and Strominger, 1989) . This led to the hypothesis that MHC I internalization is regulated by phosphorylation (Capps et al., 1989) , a theory that was disputed in a later study (Eichholtz et al., 1992) . More recently it was shown that the lysosomotropic drug primaquine inhibits MHC I phosphorylation as well as recycling to the cell surface (Capps and Zuniga, 2000) . These data suggest that phosphorylation either regulates or reflects MHC I trafficking to and from the cell surface in those cell types that display spontaneous MHC I internalization. Here we test the hypothesis that KSHV-K3-and KSHV-K5-mediated MHC I internalization requires signals in the cytoplasmic tail of MHC I. Our results show that phosphorylation is inhibited in KSHV-K5-transfected cells. However, deletion of the cytoplasmic tail does not prevent K5-mediated MHC I downregulation. Thus, the inhibition of phosphorylation does not cause MHC I internalization. Furthermore, the motifs required for MHC I downregulation by K3 or K5 are distinct from those required for nef-mediated internalization, thus supporting a different mechanism.
RESULTS
Diminished phosphorylation of MHC I in K5-transfected HeLa cells
To determine whether the phosphorylation/dephosphorylation status of MHC I molecules is changed in K3-and K5-transfected cells, we amplified KSHV-K3 and KSHV-K5 DNA by polymerase chain reaction (PCR) using DNA isolated from KSHV-infected dermal vascular endothelial cells (Moses et al., 1999) . The PCR fragments were cloned under the control of a tetracycline-regulated promoter and transfected into tet-transactivator-containing HeLa cells (Gossen and Bujard, 1992) . The downregulation of MHC I molecules by K3 and K5 was confirmed by flow cytometry using the MHC I-specific antibody W6/32 (Parham et al., 1979) . As shown in Fig. 1A (top), surface expression of MHC I was greatly diminished upon transfection of either K3 or K5 constructs. In transient transfection experiments, only those cells that had received the expression plasmids showed MHC I downregulation.
To examine the phosphorylation status of MHC I molecules, we focused our efforts on KSHV-K5 for reasons discussed below. We generated stably K5-transfected HeLa cells. Upon removal of tetracycline, MHC I surface levels were reduced due to induction of K5 (Fig. 1A,  bottom) . Using this stable cell line we performed in vivo labeling with 33 P followed by immunoprecipitation using W6/32. MHC molecules immunoprecipitated from nontransfected HeLa cells were clearly phosphorylated (Fig.  1B) . In contrast, phosphorylation was significantly reduced in cells transfected with K5 (Fig. 1B) . These results suggested that phosphorylation of MHC I was inhibited by K5. However, the diminished phosphorylation could simply reflect the reduced amount of MHC I molecules present in these cells as a consequence of increased internalization and subsequent lysosomal degradation (Coscoy and Ganem, 2000; Ishido et al., 2000b) . The overall amount of MHC I molecules in K5-transfected cells was therefore assessed either by labeling with 35 S for 2 or 16 h prior to immunoprecipitation (Fig. 1C) or by immunoblotting MHC molecules from stable K5-transfected HeLa cells (Fig. 1D) . These experiments showed that the overall amount of MHC I molecules was diminished in K5 transfectants. Quantification by gel-scanning (Eagle Eye) revealed a twofold reduction of MHC I heavy chains in K5 transfectants, whereas no difference in transferrin receptor amounts was measured. In contrast, the difference between phosphorylated MHC I and nonphosphorylated MHC I (Fig. 1B ) was more than 10-fold. Therefore we conclude that phosphorylation of MHC I molecules is inhibited in K5 transfectants. Similarly, we observed a reduction of MHC I phosphorylation in K3 transfectants (not shown). However, the overall reduction of MHC I molecules due to degradation was not significantly different from the reduction of phosphorylation. Therefore, we could not distinguish experimentally between degradation and inhibition of phosphorylation in K3 transfectants.
The PHD/LAP domain is required to inhibit MHC I phosphorylation
The primary structure of K3 and K5 reveals a conserved amino-terminal domain that contains a sequence motif known as the plant homeodomain (PHD) (Aasland et al., 1995) or leukemia-associated protein (LAP) domain (Saha et al., 1995) . The PHD/LAP finger consensus sequence is represented by C1-Xaa1-2-C2-Xaa9-21-C3-Xaa2-4-C4-Xaa4-5-H5-Xaa2-C6-Xaa2-C8 (abbreviated Cys4-His-Cys3), with numbers representing the numbers of amino acid residues between the conserved cysteine and histidine residues. Point mutations in the PHD/LAP domain of human proteins are associated with genetic diseases (Gibbons et al., 1997; Lu et al., 1998) . The sequence conservation of the PHD/LAP domains suggests that they play a crucial role either in MHC downregulation or in the subcellular localization of K3 and K5. The recently determined solution structure of a PHD/LAP domain revealed an interlaced type of zinc finger whereby the highly conserved cysteine and histidine residues form a complex with two zinc atoms (Pascual et al., 2000) . To test whether the PHD/LAP domain is required for the observed lack of phosphorylation in HLA molecules, we replaced the first two cysteines of the PHD/LAP motif with serines in the K5 sequence by sitedirected mutagenesis. Equivalent mutations were shown to destroy the zinc-binding properties in other proteins (Blumberg et al., 1987) . Replacement of the two residues in K5 was confirmed by sequence analysis.
Upon transfection into HeLa cells, the PHD mutant was unable to affect the phosphorylation status of MHC I ( Fig. 2A) . The mutant protein was also unable to reduce MHC I surface expression (Fig. 1) . It was possible that these point mutations resulted in a mislocalization or misfolding and rapid degradation of mutant K5. Therefore, we examined the stability of mutated K5 by pulsechase labeling followed by immunoprecipitation using K5 constructs that were FLAG-epitope-tagged at their carboxy-terminus. Previously it was shown that such tagging does not affect the function of K5 (Coscoy and Ganem, 2000) . As shown in Fig. 2B , the mutations did not prevent expression of K5. We further examined the intracellular localization of mutated K5 by immunofluorescence microscopy. Both wildtype and mutant K5 colocalized with calreticulin in the ER (Fig. 3 ). However, a portion of the mutant protein stained separately from calreticulin, suggesting that the K5 mutant had a slightly altered intracellular localization compared to wildtype K5. We do not know whether this subtle change in intracellular location plays a role in the malfunction of the mutant protein. The ER localization of the wildtype protein is in agreement with previous observations in HeLa cells (Coscoy and Ganem, 2000) , but contrasts with a surface localization described for BJAB cells (Ishido et al., 2000b) . We conclude that the PHD/LAP domain is essential for K5-mediated internalization of MHC I molecules, consistent with its role in the internalization of B7 and ICAM-1 (Ishido et al., 2000a) . Different regions of the MHC I cytoplasmic tail are required for phosphorylation and K5-or K3-mediated internalization MHC I molecules are not phosphorylated until they reach the cell surface. Specifically, phosphorylation is absent from MHC molecules before they traverse the Golgi apparatus (Loube et al., 1983) . Moreover, MHC I molecules remain phosphorylated upon internalization and recycling, whereas inhibition of recycling by primaquine inhibits phosphorylation (Capps and Zuniga, 2000) . However, it is not clear whether dephosphorylation simply reflects the inhibition of MHC I recycling or whether there is a causative relationship between recycling and phosphorylation. Further complicating these issues are observations that suggest that the phosphorylation and dephosphorylation of MHC I are cell type-dependent (Capps et al., 1989) . To examine whether or not the observed inhibition of phosphorylation in K5-transfected cells is important for the internalization of MHC I molecules, we generated a set of mutants in the cytoplasmic tail of the human MHC I molecule HLA-A2.1.
The series of mutants generated is shown in Table 1 . The two mutants with tail deletions corresponding to exon 6 and exon 7 of HLA-A2.1 were described previously (Le Gall et al., 1998) . The other mutants were generated by PCR-directed mutagenesis. In mutants TM1-TM4, serines that are potentially phosphorylated were mutated in groups of two. Mutants d311-d331 were generated by truncating HLA-A2.1 and simultaneously adding the HA tag to the carboxy-terminus. All mutations were verified by sequence analysis.
To analyze whether or not the resulting constructs could be phosphorylated, we transfected cells with the respective constructs followed by [
33 P]orthophosphate labeling and immunoprecipitation with BB7.2, an antibody specific for HLA-A2.1 (Parham and Brodsky, 1981) . Since HeLa cells do not express endogenous HLA-A2.1, only transfected molecules will be recovered. To control for expression, we performed metabolic labeling with [
35 S]methionine in parallel. The results are shown in Fig.  4 . Expression of all constructs was comparable and readily detectable (Fig. 4, bottom) . Moreover, all constructs were transported to the cell surface (see below). However, the amount of phosphorylation differed significantly depending on the construct (Fig. 4, top) . All constructs that contained the two carboxy-terminal serines were strongly phosphorylated. Removal of these two serines either by point mutation (TM4) or by deletion mutagenesis (d331) resulted in a greatly diminished phosphorylation. However, complete loss of phosphorylation was observed only when six of the eight serines were removed by deletion (d318). These results are consistent with the observation that the main phosphorylation site of MHC I is serine 335, which was removed in mutant TM4 (Guild and Strominger, 1984b) . However, they also show that additional, albeit weaker, phosphorylation can take place at other conserved serines within the cytoplasmic tail.
To test which of these mutants could still be downregulated by KSHV-K5 and KSHV-K3, we cotransfected each mutant construct or vector control (pBI) and analyzed the surface expression of HLA-A2.1 by flow cytometry. To distinguish between transfected and nontransfected cells, we further cotransfected an expression construct for green fluorescent protein. The results are summarized in Table 1 . Surprisingly, all mutant HLA-A2.1 constructs were downregulated by K5. In contrast, K3 was unable to downregulate d311, which carries the shortest cytoplasmic tail. The different capability of K3 and K5 to downregulate mutants d311 and d318 is also shown in Fig. 5 by plotting the anti-HLA-A2.1 fluorescence against the GFP fluorescence. A clear reduction of d318 HLA-A2.1-positive cells was observed upon cotransfection with K3 and K5, whereas no effect on GFP fluorescence was observed. In contrast, d311 fluorescence was reduced by K5 but not by K3. These results suggest (a) that neither K3 nor K5 requires any parts of the cytoplasmic tail that are phosphorylated in order to downregulate MHC I and (b) that K3 and K5 differ in their requirement for the involvement of the cytoplasmic tail of MHC I. Whereas K3 requires a short stretch of HLA-A2.1-specific cytoplasmic tail amino acids, K5 is able to downregulate MHC I that almost completely lacks the HLA-A2.1-specific cytoplasmic tail. We conclude that the inhibition of MHC I phosphorylation is a result of the increased internalization of MHC I molecules but does not cause it.
DISCUSSION
The observation that MHC I phosphorylation is inhibited in K5-transfected cells is most likely the result of a series of events: MHC I molecules travel to the cell surface normally, but are rapidly internalized. Normal exit and rapid internalization have been well documented previously (Coscoy and Ganem, 2000; Ishido et al., 2000b) . Internalized MHC I molecules are not degraded immediately, but dwell in endosomal vesicles before being degraded in lysosomes. This conclusion is supported by the fact that the half-life of MHC I molecules in K3-and K5-transfected cells is several hours, whereas FIG. 3 . The PHD/LAP domain mutant of K5 primarily localizes to the ER. HeLa-tet TA cells were transiently transfected with the K5 wildtype or mutant constructs. The transfected cells were stained with a primary FLAG antibody and secondary Alexa 488 (green) antibody, as well as with a primary calreticulin antibody (calreticulin is an ER-specific protein) and a secondary Alexa 568 (red) antibody. The stained cells were examined with a confocal microscope. 
Note. Experiments were performed as described in the legend to Fig. 5 . Mean immunofluorescence values that reflect MHC downregulation are shown in boldface type. the internalization takes place rapidly within minutes (Coscoy and Ganem, 2000; Ishido et al., 2000b; and unpublished observations) . Thus, the main part of the MHC I population resides in intracellular vesicles. Therefore, it seems likely that the dephosphorylated population described here represents internalized MHC I molecules destined for degradation. This interpretation would be consistent with the observation that inhibition of intracellular degradation by primaquine also results in the accumulation of a dephosphorylated population of MHC I molecules (Capps and Zuniga, 2000) . These authors further concluded that the MHC I molecules remain phosphorylated if they recycle back to the cell surface, but are dephosphorylated if they are destined for degradation. Therefore, we conclude that the dephosphorylated MHC I molecules in K5-expressing cells (and most likely also in K3-transfected cells) represent an intermediate between internalization and degradation.
Our data further indicate that the K3-and K5-mediated internalization also occurs in the absence of the phosphorylation sites in the MHC I tail suggesting that the inhibition of MHC I tail phosphorylation is indicative of MHC I internalization by the viral proteins, but not causative. The result that the cytoplasmic tail of MHC I is not required for K5-mediated internalization also shows that the internalization mechanism is quite distinct from that of nef. The two HLA-A2.1 mutants ⌬6 and ⌬7 were previously used to map the sites required for nef-mediated internalization (Le Gall et al., 1998) . The cytoplasmic tail is encoded by two distinct exons that are deleted in these mutants. It was found that the exon 6-deleted mutant was no longer internalized in the presence of nef, in contrast to the exon 7-deleted mutant. However, neither K3 nor K5 required this internalization signal to be present for MHC I downregulation. Furthermore, hybrids between the MHC I carboxy-terminal domain, including the transmembrane domain and the cytoplasmic domain, with the luminal domain of CD8 were still downregulated by K3 and K5 (Ishido et al., 2000b) . Taken together with our data, it seems that the minimal signals required for 
FIG. 5.
Deletion of phosphorylation sites does not prevent MHC I downregulation by KSHV K3 and KSHV K5. HeLa-tet TA cells were transiently transfected with the HLA A2.1 wildtype or mutant constructs, along with pBI (vector plasmid), K3, or K5, as well as with 10-fold less GFP expression plasmid. At 48 h posttransfection, the cells were stained with a primary mouse anti-human HLA-A2.1 monoclonal antibody (BB7.2) followed by a secondary PE-conjugated anti-mouse IgG antibody and then analyzed by FACS. Cells were gated on GFP and analyzed for PE staining (A2.1 expression). The FACS dot plots for the A2, d311, and d318 constructs are shown; the FACS results for the other mutants are presented in Table 1. K5-mediated internalization reside mostly in the transmembrane domains of MHC I. In contrast, K3 seems to require an additional stretch of amino acids in the HLA-A2.1 cytoplasmic region. Previous observations also indicated that K3 and K5 differ with respect to their allele specificity. Whereas K3 did not discriminate between human alleles, K5 showed a preference for HLA-A and HLA-B alleles. Our mapping experiments indicate that the allele specificity of K5 could not be caused by sequences in the cytoplasmic domain since all three human alleles are identical in the minimal cytoplasmic region mapped in this study. However, HLA alleles differ in their transmembrane domain, thus further supporting a pivotal role of the transmembrane domain for K5-mediated MHC downregulation. A possible explanation for this role is that K5 and K3 may interact at some point with MHC I molecules (either directly or indirectly). This interaction would most likely involve specific regions in the transmembrane domain and, at least for K3, the membrane-proximal domain of the MHC I tail. However, such an interaction still needs to be demonstrated.
Therefore, it can only be speculated by what molecular mechanism K3 and K5 induce the internalization of MHC I molecules. If the two viral proteins are strictly ERresident, as most current data, including ours, seem to suggest, one could speculate that the viral proteins introduce a modification into the MHC I transmembrane domain and membrane-proximal cytoplasmic domain that serves as an internalization signal. Work is in progress to detect such a modification. Alternatively, the viral proteins could employ a cellular protein to act on this region of the MHC I molecule. Either case represents an entirely novel molecular mechanism to escape immune detection by cytotoxic T cells.
MATERIALS AND METHODS
Construction of plasmids
The K3 and K5 open reading frames were both PCRamplified with Vent polymerase, using genomic DNA from KSHV-infected endothelial cells as a template. The C-terminal FLAG-tagged K3 PCR product was generated with the following primers: 5Ј K3 Nhe, 5Ј-GGC-GGC-TAG-CAT-GGA-AGA-TGA-GGA-TGT-TCC-3Ј; 3Ј K3 C-FLAG, 5Ј-GTC-GCC-CGG-GTC-ACT-TGT-CGT-CGT-CGT-CCT-TGT-AGT-CAT-GAA-ACA-TAA-GGG-CAG-3Ј. This PCR product was cloned into the PCR-blunt vector (Invitrogen, Carlsbad, CA) and cut out with NheI and SpeI. The SpeI site was blunted with Klenow, allowing this fragment to be cloned between the NheI and EcoRV sites of the pBI tetracycline-regulated expression plasmid (Clontech, Palo Alto, CA). All of the plasmids were confirmed by sequencing.
The C-terminal FLAG-tagged K5 PCR product was also generated by PCR with Vent polymerase, using genomic DNA from KSHV-infected endothelial cells and the following PCR primers: 5Ј K5 Nhe, 5Ј-GGC-GGC-TAG-CAT-GGC-GTC-TAA-GGA-CGT-AGA-3Ј; 3Ј K5 C-FLAG, 5Ј-GTC-GGA-TAT-CTC-ACT-TGT-CGT-CGT-CGT-CCT-TGT-AGT-CAC-CGT-TGT-TTT-TTG-GAT-GA-3Ј. This PCR fragment was initially cloned into the PCR-blunt vector (Invitrogen), cut out with NheI and EcoRV, and cloned between the NheI and EcoRV sites of the pBI vector (Clontech).
The FLAG-tagged K5 PHD/LAP mutant plasmid was generated using the QuikChange site-directed PCR mutagenesis kit (Stratagene, La Jolla, CA). To convert the first two conserved cysteines in the PHD/LAP motif into serines, PCR was performed on K5-FLAG/pBI plasmid DNA with Pfu-turbo and the following mutagenic primers: 5Ј K5 CmS, 5Ј-GAG-GGA-CCC-ATC-TCC-TGG-ATA-TCC-AGG-GAA-GAG-GTG-3Ј; 3Ј K5CMS, 5Ј-CAC-CTC-TTC-CCT-GGA-TAT-CCA-GGA-GAT-GGG-TCC-CTC-3Ј. The 261-bp NheI/XmnI fragment of K5 containing these mutations, as well as the XmnI/BglII fragment of K5-FLAG/ pBI, was joined in a three-part ligation between the NheI and BglII sites of the pBI vector.
To make the wildtype HLA-A2.1 construct, the EcoRI/ XbaI fragment of A2.1 (from bp 429 to 2285), which includes the open reading frame as well as some additional flanking sequence, was cloned between the EcoRI and XbaI sites of the tetracycline-regulated vector pUHD10.1 (Gossen and Bujard, 1992) . The A2.1 tail deletion constructs were generated by PCR amplification, with Vent polymerase, from the wildtype A2.1 plasmid. The constructs were truncated at bp 1442 (aa 311), bp 1463 (aa 318), bp 1481 (aa 324), or bp 1502 (aa 331). The PCR product included a natural StuI site (bp 1212 of A2.1) near the 5Ј end, the indicated amount of A2.1 sequence, and a C-terminal HA tag as well as an engineered SphI site (bp 1553) in the 3Ј primer. The same 5Ј primer (5Ј A2Stu, bp 1188 of A2: 5Ј-GAC-ACG-GAG-CTC-GTG-GAG-AC-3Ј) was used along with each of the four 3Ј primers [3Ј A2d1442 (d311): 5Ј-GTC-GGC-ATG-CTC-AGG-CGT-AGT-CGG-GCA-CGT-CGT-AGG-GGT-ACT-TCC-TCC-TCC-ACA-TCA-CAG-3Ј; 3Ј A2d1463 (d318): 5Ј-GTC-GGC-ATG-CTC-AGG-CGT-AGT-CGG-GCA-CGT-CGT-AGG-GGT-ACC-CTC-CTT-TTC-TAT-CTG-AGC-3Ј; 3Ј A2d1481 (d324): 5Ј-GTC-GGC-ATG-CTC-AGG-CGT-AGT-CGG-GCA-CGT-CGT-AGG-GGT-ATG-CAG-CCT-GAG-AGT-AGC-TCC-3Ј; 3Ј A2d1502 (d331): 5Ј-GTC-GGC-ATG-CTC-AGG-CGT-AGT-CGG-GCA-CGT-CGT-AGG-GGT-AGC-CCT-GGG-CAC-TGT-CAC-TGC-3Ј] to generate the various deletions. The PCR fragment was initially cloned into PCR-blunt, cut out with StuI and SphI, and cloned between the StuI and SphI sites of A2.1/pUHD10.1.
The TM1, TM2, TM3, and TM4 mutants were made using a PCR-based strategy described previously (Swann et al., 2001 ) with the following mutant primers: TM1, 3Ј-GCTCCCTCCTTTTCTATCTGCGGCCTTCCTCCT-CCACATCACAGC; TM1, 5Ј-GCTGTGATGTGGAGGAGGA-AGGCCGCA-GATAGAAAAGGAGGGAGC; TM2, 3Ј-GTCA-CTGCTTGCAGCCTGAGCGTAGGCCCCTCCTTTTCTATC-TGAGC; TM2, 5Ј-GCTCAGATAGAAAAGGAGGGGCCTA-CGCTCAGGCTGCAAGCAGTGAC; TM3, 3Ј-CACATCAGA-GCCCTGGGCAGCGTCAGCGCTTGCAGCCTGAGAGTA-GC; TM3, 5Ј-GCTACTCTCAGGCTGCAAGCGCTGACGCT-GCCCAGGGCTCTGATGTG; TM4, 3Ј-CACTTTACAAGCT-GTGAGAGCCACATCAGCGCCCTGGGCACTGTCAC-TGC; and TM4, 5Ј-GCAGTGACAGTGCCCAGGGCGCTGA-TGTGGCTCTCACAGCTTGTAAAGTG) .
Briefly, 5Ј and 3Ј overlapping mutant fragments were synthesized in separate reactions. Then, in a second reaction, the fragments were mixed and the full-length fragment was amplified. The primers used to make the 5Ј fragment were as follows: upstream primer (5Ј-GCAGCT-CAGACCACCAAGCACAAG-3Ј) and a 3Ј mutant primer. The primers used to make the 3Ј fragment were as follows: downstream primer (5Ј-TAGAAGGCACAGTC-GAGG-3Ј) and a 5Ј mutant primer. In the second PCR, the overlapping mutant fragments were mixed together with upstream and downstream primers. The resulting fragment was digested with XhoI and PmlI and cloned back into the HLA-A2-pcDNA expression vector (obtained from Dr. Hidde Ploegh's laboratory). The resulting construct was sequenced to ensure that only the intended alteration had been made.
The A2⌬6 and A2⌬7 constructs (Le Gall et al., 1998) were kindly provided by Olivier Schwartz.
Cell culture and transient transfections
HeLa-tet TA cells were maintained in DMEM with 10% tet-free FCS (Clontech), glutamine, pen/strep/antifungal drug (Gibco BRL, Rockville, MD), and 100 g/ml G418 (Calbiochem, San Diego, CA). Transfections were performed using the Effectene kit (Qiagen, Valencia, CA). The day before transfections, 10 6 cells were plated in 100-mm tissue culture dishes. Cells were transfected with a total of 2 g DNA per 100-mm dish, according to the standard adherent cell transfection protocol outlined in the Effectene kit handbook. For GFP cotransfections, 10-fold less GFP plasmid was used, to ensure that the GFP-positive cells would also contain the other plasmid(s) of interest. Six to 18 h after transfections, cells were washed once with PBS and given fresh medium. At 48 h posttransfection, cells were trypsinized, if necessary, and utilized in the assay of interest.
Generation of the K5 stable cell line
HeLa-tet TA cells were transfected using a calcium phosphate kit (Invitrogen). The K5 C-FLAG/pBI plasmid was linearized with FspI, and a plasmid carrying resistance to Ouabain (Früh et al., 1994) was linearized with ScaI; the linearized plasmids were then purified using the QIAquick PCR purification kit (Qiagen). Cotransfections were performed with 20 g of linearized K5 C-FLAG/pBI and 1 g of linearized Ouabain resistance plasmid, or, as a control, with the linearized Ouabain resistance plasmid alone. The transfected cells were grown in medium containing 1 g/ml tetracycline, to repress expression of K5-FLAG. Three days posttransfection, the cells were trypsinized and split at ratios of 1:3, 1:6, and 1:9 in 100-mm dishes. Twice a week, the cells were exposed overnight to medium containing 1 M Ouabain, to kill the nontransfected cells. Two and a half weeks later, when sizable colonies were readily apparent on the plates, cloning rings were used to isolate individual cell clones and expand them in 12-well plates. To screen for tetracycline-repressible K5 expression, cells were washed three times with PBS to remove tetracycline, grown in either tetracycline-free or tetracycline-containing medium for 2 days, and analyzed by FACS for MHC I. Expression of K5-FLAG was then confirmed by immunofluorescence and immunoprecipitations with the FLAG M2 monoclonal antibody (Sigma, St. Louis, MO).
Flow cytometry
A total of 7.5 ϫ 10 5 detached cells were washed two times with PBS and resuspended in a blocking solution of 10% human serum in calcium/magnesium-free PBS for 15 min on ice. The cells were stained with the primary antibody in blocking solution for 25 min on ice and washed with PBS. Then, if necessary, cells were stained with a secondary PE-conjugated anti-mouse IgG antibody (Sigma) for 25 min on ice. The stained cells were washed twice with PBS and fixed with 1% formaldehyde in PBS. To assess expression of MHC I on HeLa-tet TA cells, the W6/32 mouse anti-human Class I monoclonal antibody (Sigma) was utilized (either the FITC-conjugated form or, for GFP cotransfections, the unconjugated form-10 l of antibody was sufficient to stain 10 6 cells). To detect HLA A2.1, the mouse monoclonal antibody BB7.2 was used at a final concentration of 10 g/ml. A PE-conjugated anti-mouse IgG antibody (Sigma), diluted 1:100, served as a secondary detection reagent. FACS analysis was performed on a Becton Dickinson FACScan flow cytometer (Bedford, MA) with CellQuest software.
P labeling and immunoprecipitations
HeLa-tet TA cells, K5/HeLa-tet TA stable cells, and transfected HeLa-tet TA cells were grown to 90% confluency in 100-mm tissue culture dishes, placed in phosphate-free medium (Gibco BRL, Rockville, MD) for 1 h, and labeled with 500 Ci of [ 33 P]orthophosphate (NEN, Boston, MA) in 1 ml of phosphate-free medium for 2 h. The labeled cells were placed on ice, washed twice with cold PBS (supplemented with phosphatase inhibitors), and lysed for 1 h with 1 ml of a 1% Triton X-100/PBS buffer containing protease inhibitor tablets (Roche, Indianapolis, IN) and a cocktail of serine/threonine phosphatase inhibitors (Sigma). The cell lysates were immunoprecipitated with either 15 l (3 g) of the W6/32 mouse anti-human Class I monoclonal antibody (Sigma), or 5 g of the mouse anti-human HLA A2 monoclonal antibody BB7.2 (obtained from Didier LeTurq). The immune complexes were bound to protein A-Sepharose (Amersham Pharmacia Biotech, Piscataway, NJ), washed three times in wash buffer (containing 0.1% Triton X-100, protease inhibitor tablets, and phosphatase inhibitor cocktail), and resuspended in 2ϫ SDS sample buffer (Invitrogen) (supplemented with 0.2 M DTT. The immunoprecipitated complexes were then heated at 55°C for 5 min and analyzed by SDS-PAGE on 10-20% Tris-glycine gradient gels (Invitrogen). The gels were fixed, dried, and exposed to film using a Kodak BioMax Transcreen-LE intensifying screen.
S labeling and immunoprecipitations
Cells were grown to 90% confluency in 100-mm tissue culture dishes, exposed to methionine-free medium (Gibco BRL) for 30 min, and labeled with 400 Ci of 35 S protein labeling mix (NEN) in 1 ml of methionine-free medium for 30 min (or for 2 or 16 h as indicated). (In the overnight labeling experiments, 1% FCS was also included in the medium.) After the labeling, cells were washed twice with PBS and either lysed directly, in PBS containing 1% Triton X-100 and protease inhibitor tablets (Roche), or chased with regular medium for the indicated times and then lysed. The cell lysates were immunoprecipitated with 15 l (3 g) of the W6/32 mouse antihuman Class I monoclonal antibody (Sigma), 5 g of the FLAG M2 monoclonal antibody (Sigma), or 5 g of the HLA A2 monoclonal antibody BB7.2 (obtained from Didier LeTurq). The immunoprecipitated complexes were bound to protein-Sepharose or protein G-Sepharose (Amersham Pharmacia Biotech), washed three times in wash buffer (containing 0.1% Triton X-100 and protease inhibitor tablets), and resuspended in 2ϫ SDS sample buffer (Invitrogen) supplemented with 0.2 M DTT. The immunoprecipitated complexes were then boiled for 5 min and analyzed by SDS-PAGE on 10-20% Tris-glycine gradient gels (Invitrogen). The gels were fixed, dried, and exposed to film as above.
Immunofluorescence
HeLa-tet TA cells were transiently transfected with the wildtype or mutant K5-FLAG construct. At 48 h posttransfection, the cells were detached with cell dissociation buffer (Gibco BRL) and grown overnight on tissue culture-treated glass coverslips (Becton Dickinson) in 6-well plates. The following day, the cells were fixed with 4% formaldehyde in calcium/magnesium-free PBS, quenched with 50 mM NH 4 Cl in PBS, and permeabilized with 0. 1% Triton X-100 in PBS. Antibody staining was carried out in PBS containing 1% fetal calf serum. The FLAG M2 mouse monoclonal antibody (Sigma) was used at a dilution of 1:250, to detect the FLAG-tagged K5 proteins. The rabbit anti-human calreticulin antibody (StressGen, Victoria, British Columbia, Canada) was used at a 1:200 dilution. A secondary 488 Alexa fluorophore-conjugated anti-mouse IgG F(abЈ) 2 antibody (Molecular Probes, Eugene, OR) was used at a concentration of 4 g/ml to detect the primary FLAG antibody, while a secondary 568 Alexa fluorophore-conjugated anti-rabbit IgG antibody (Molecular Probes) was utilized at 4 g/ml for the detection of the primary calreticulin antibody. The coverslips were mounted on slides using Gel-Mount (Biomeda, Foster City, CA), and the stained cells were examined by confocal microscopy.
Immunoblots
Cells were grown to 90% confluency in 100-mm tissue culture dishes, trypsinized, and counted. A total of 5 ϫ 10 6 cells were lysed in 250 l of 2ϫ SDS sample buffer containing 0.2 M DTT and boiled for 10 min. The lysates were run over Qiashredder columns (Qiagen). Then 12 l of the lysate was run on a 10-20% Tris-glycine gel (Invitrogen) with 1ϫ Tris-glycine-SDS running buffer, and the separated proteins were transferred to a 0.45-m nitrocellulose membrane (Bio-Rad, Hercules, CA). The Western blots were carried out using the Immun-Star chemiluminescent alkaline phosphatase kit (Bio-Rad), except that 5% nonfat dry milk in TBS and TTBS was used instead of the recommended 0.2%. For detection of MHC I, the polyclonal rabbit antibody K455 was used, at a dilution of 1:2000, followed by a secondary alkaline phosphatase-conjugated anti-rabbit Ig antibody, diluted 1:3030. For detection of the transferrin receptor, a monoclonal mouse anti-human CD71 antibody (BD PharMingen, Hercules, CA) was utilized at a 1:500 dilution, followed by a secondary alkaline phosphataseconjugated anti-mouse Ig antibody, diluted 1:3030.
